MedTrace Logo

Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Bone Marrow Transplantation Patients

NCT00578630 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2018-11-19

No results posted yet for this study

Summary

The purpose of this study is to develop tests that will allow us to determine who will react differently to the drugs used to treat cancer. We also want to see who will react differently with preparing for a bone marrow transplant.

Conditions

  • Neoplasms

Interventions

OTHER

buccal swabs and obtaining peripheral blood

will be the collection of normal cells and assessments of toxicity following chemotherapy at routine clinic visits.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • American Cancer Society, Inc.

    collaborator OTHER

  • Montefiore Medical Center

    collaborator OTHER

  • Memorial Sloan Kettering Cancer Center

    lead OTHER

Principal Investigators

  • Paul Meyers, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-14
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00578630 on ClinicalTrials.gov